Portfolio Alerts Watch List Cart

Pharmaceutical

Refine Search

Product Compare (0)
N
Nectar Lifesciences Ltd
Score 68/100• Decent
Nectar Lifesciences Ltd shows potential in a growing sector, but faces challenges in consistency and valuation, warranting cautious observation.
Company’s Health27/100
Valuation 100/100 · PB 0.4935
Technical Avoid
1M 40.82% 6M -13.756% 1Y -40.41%
Confidence100%
Reasonable PB valuation
Weak ROEPromoter pledge present
#76
View details ➜
M
Makers Laboratories Ltd
Score 68/100• Decent
Makers Laboratories Ltd shows potential for growth in a favorable sector, but faces challenges in profitability and valuation metrics.
Company’s Health64/100
Valuation 100/100 · PB 0.6249
Technical Avoid
1M 0.083% 6M -21.29% 1Y -23.655%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROEThin margins
#77
View details ➜
L
Laurus Labs Ltd
Score 68/100• Decent
Laurus Labs Ltd shows potential for growth in a promising sector, but faces challenges in profitability and valuation metrics.
Company’s Health68/100
Valuation 20/100 · PB 11.8739
Technical Watch
1M 3.053% 6M 51.826% 1Y 79.549%
Confidence100%
Weak ROEPromoter pledge present
#78
View details ➜
J
Jubilant Pharmova Ltd
Score 68/100• Decent
Jubilant Pharmova Ltd shows potential for growth but faces challenges in profitability and valuation. Investors should be cautious.
Company’s Health54/100
Valuation 60/100 · PB 2.7552
Technical Avoid
1M -2.924% 6M -3.518% 1Y -3.45%
Confidence100%
Low leverage (D/E)Decent revenue growth
Promoter pledge present
#79
View details ➜
J
Jagsonpal Pharmaceuticals Ltd
Score 68/100• Decent
Jagsonpal Pharmaceuticals Ltd shows potential but faces significant challenges in profitability and valuation metrics. Caution is advised for investors.
Company’s Health94/100
Valuation 20/100 · PB 5.6345
Technical Avoid
1M -5.857% 6M -13.858% 1Y -23.65%
Confidence100%
Low leverage (D/E)No promoter pledge
#80
View details ➜
J
J B Chemicals and Pharmaceuticals Ltd
Score 68/100• Decent
J B Chemicals and Pharmaceuticals Ltd shows decent potential with a stable growth outlook, but investors should be cautious of execution risks and valuation metrics.
Company’s Health95/100
Valuation 20/100 · PB 8.2037
Technical Avoid
1M -0.253% 6M 3.02% 1Y -2.322%
Confidence100%
Low leverage (D/E)No promoter pledge
#81
View details ➜
I
IPCA Laboratories Ltd
Score 68/100• Decent
IPCA Laboratories Ltd shows potential for growth, but investors should be cautious due to profitability inconsistencies and valuation concerns.
Company’s Health80/100
Valuation 40/100 · PB 4.4336
Technical Avoid
1M 11.915% 6M 5.994% 1Y -6.062%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROE
#82
View details ➜
I
Indoco Remedies Ltd
Score 68/100• Decent
Indoco Remedies Ltd shows potential for growth but faces challenges in profitability and valuation metrics.
Company’s Health56/100
Valuation 60/100 · PB 2.195
Technical Avoid
1M -10.586% 6M -13.499% 1Y -27.629%
Confidence100%
No promoter pledgeReasonable PB valuation
Weak ROEThin margins
#83
View details ➜
H
Hindustan Bio Sciences Ltd
Score 68/100• Decent
Hindustan Bio Sciences Ltd shows potential but faces significant challenges in growth and profitability metrics. Caution is advised for investors.
Company’s Health33/100
Valuation 20/100 · PB 6.9364
Technical Avoid
1M -18.245% 6M -34.586% 1Y -41.103%
Confidence100%
No promoter pledgeHealthy profit margins
Weak ROEHigh debt/equity
#84
View details ➜
G
Gufic Biosciences Ltd
Score 68/100• Decent
Gufic Biosciences Ltd shows potential for growth in a promising sector, but faces challenges in profitability and valuation metrics. Investors should proceed with caution.
Company’s Health90/100
Valuation 20/100 · PB 5.8094
Technical Avoid
1M 8.501% 6M -6.599% 1Y -20.009%
Confidence100%
No promoter pledge
#85
View details ➜
F
Fortis Healthcare Ltd
Score 68/100• Decent
Fortis Healthcare Ltd shows potential in a growing sector but faces challenges in execution and competition. Caution is advised.
Company’s Health67/100
Valuation 20/100 · PB 7.1965
Technical Avoid
1M -14.543% 6M 15.007% 1Y 21.177%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROE
#86
View details ➜
D
Dr Lalchandani Labs Ltd
Score 68/100• Decent
Dr Lalchandani Labs Ltd shows potential in a growing sector, but faces challenges in growth consistency and valuation metrics. Caution is advised.
Company’s Health46/100
Valuation 100/100 · PB 0.7834
Technical Avoid
1M -6.4% 6M 15.026% 1Y 10.64%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROE
#87
View details ➜
D
DocMode Health Technologies Ltd
Score 68/100• Risky
DocMode Health Technologies Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
Company’s Health40/100
Valuation 60/100 · PB 2.5876
Technical Avoid
1M -35.546% 6M 10.709% 1Y -26.901%
Confidence100%
Reasonable PB valuation
Weak ROEPromoter pledge present
#88
View details ➜
C
Concord Biotech Ltd
Score 68/100• Decent
Concord Biotech Ltd shows potential for growth but faces challenges in valuation and execution risks.
Company’s Health94/100
Valuation 20/100 · PB 7.9054
Technical Avoid
1M -6.42% 6M -33.621% 1Y -36.064%
Confidence100%
Low leverage (D/E)No promoter pledge
#89
View details ➜
B
Bharat Parenterals Ltd
Score 68/100• Decent
Bharat Parenterals Ltd shows potential for growth, but faces challenges in profitability and market competition.
Company’s Health64/100
Valuation 60/100 · PB 2.2949
Technical Avoid
1M -3.313% 6M -9.144% 1Y -35.65%
Confidence100%
No promoter pledgeDecent revenue growth
Weak ROEThin margins
#90
View details ➜
Showing 76 to 90 of 260 (18 Pages)